Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review

被引：0

作者：

Oki, Ryosuke ^{[1
]}

Takemura, Kosuke ^{[2
]}

Urasaki, Tetsuya ^{[1
]}

Fujiwara, Ryo ^{[2
]}

Numao, Noboru ^{[2
]}

Yonese, Junji ^{[2
]}

Miura, Yuji ^{[1
]}

Yuasa, Takeshi ^{[2
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan

[2] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Genitourinary Oncol, 3-8-31 Ariake,Koto Ku, Tokyo 1358550, Japan

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2025年 / 25卷 / 06期

关键词：

Combined modality therapy; immunotherapy; kidney neoplasms; molecular targeted therapy; renal cell carcinoma; COMPREHENSIVE MOLECULAR CHARACTERIZATION; ADJUVANT PEMBROLIZUMAB; GENOMIC ALTERATIONS; OPEN-LABEL; SUNITINIB; CANCER; CABOZANTINIB; NEPHRECTOMY; EVEROLIMUS; NIVOLUMAB;

D O I：

10.1080/14737140.2025.2491647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IntroductionThe management of metastatic renal cell carcinoma (mRCC) has advanced with recent therapies, yet optimizing treatment remains challenging due to disease heterogeneity and the growing number of options. Integrating systemic and local treatments requires a multidisciplinary approach to improve outcomes.Area coveredThis review summarizes recent developments in treatment for mRCC. Upfront immuno-oncology (IO)-based combinations have improved survival, though concerns about overtreatment and toxicity persist. While the role of cytoreductive nephrectomy (CN) has declined to some extent, it may still benefit well-selected patients. Metastasis-directed therapies, including metastasectomy and stereotactic radiotherapy, provide prognostic value, particularly for oligometastatic lesions or brain metastases. Comprehensive genomic profiling (CGP) holds promise for personalized treatment but is currently limited by the lack of actionable mutations and predictive biomarkers.Expert opinionA personalized, multimodal approach is essential for optimizing mRCC management. Careful patient selection is key to balancing the benefits of treatment with the risks of toxicity. While CN and metastasis-directed therapies remain useful in select cases, advancing individualized care requires the development of validated biomarkers and broader application of CGP.

引用

页码：643 / 655

页数：13

共 100 条

[21] Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes [J].

Dalgliesh, Gillian L. ;

Furge, Kyle ;

Greenman, Chris ;

Chen, Lina ;

Bignell, Graham ;

Butler, Adam ;

Davies, Helen ;

Edkins, Sarah ;

Hardy, Claire ;

Latimer, Calli ;

Teague, Jon ;

Andrews, Jenny ;

Barthorpe, Syd ;

Beare, Dave ;

Buck, Gemma ;

Campbell, Peter J. ;

Forbes, Simon ;

Jia, Mingming ;

Jones, David ;

Knott, Henry ;

Kok, Chai Yin ;

Lau, King Wai ;

Leroy, Catherine ;

Lin, Meng-Lay ;

McBride, David J. ;

Maddison, Mark ;

Maguire, Simon ;

McLay, Kirsten ;

Menzies, Andrew ;

Mironenko, Tatiana ;

Mulderrig, Lee ;

Mudie, Laura ;

O'Meara, Sarah ;

Pleasance, Erin ;

Rajasingham, Arjunan ;

Shepherd, Rebecca ;

Smith, Raffaella ;

Stebbings, Lucy ;

Stephens, Philip ;

Tang, Gurpreet ;

Tarpey, Patrick S. ;

Turrell, Kelly ;

Dykema, Karl J. ;

Khoo, Sok Kean ;

Petillo, David ;

Wondergem, Bill ;

Anema, John ;

Kahnoski, Richard J. ;

Teh, Bin Tean ;

Stratton, Michael R. .

NATURE, 2010, 463 (7279) :360-363

[22]

Dason Shawn, 2023, Am Soc Clin Oncol Educ Book, V43, pe390038, DOI 10.1200/EDBK_390038

[23] The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma [J].

Davis, Caleb F. ;

Ricketts, Christopher J. ;

Wang, Min ;

Yang, Lixing ;

Cherniack, Andrew D. ;

Shen, Hui ;

Buhay, Christian ;

Kang, Hyojin ;

Kim, Sang Cheol ;

Fahey, Catherine C. ;

Hacker, Kathryn E. ;

Bhanot, Gyan ;

Gordenin, Dmitry A. ;

Chu, Andy ;

Gunaratne, Preethi H. ;

Biehl, Michael ;

Seth, Sahil ;

Kaipparettu, Benny A. ;

Bristow, Christopher A. ;

Donehower, Lawrence A. ;

Wallen, Eric M. ;

Smith, Angela B. ;

Tickoo, Satish K. ;

Tamboli, Pheroze ;

Reuter, Victor ;

Schmidt, Laura S. ;

Hsieh, James J. ;

Choueiri, Toni K. ;

Hakimi, A. Ari ;

Chin, Lynda ;

Meyerson, Matthew ;

Kucherlapati, Raju ;

Park, Woong-Yang ;

Robertson, A. Gordon ;

Laird, Peter W. ;

Henske, Elizabeth P. ;

Kwiatkowski, David J. ;

Park, Peter J. ;

Morgan, Margaret ;

Shuch, Brian ;

Muzny, Donna ;

Wheeler, David A. ;

Linehan, W. Marston ;

Gibbs, Richard A. ;

Rathmell, W. Kimryn ;

Creighton, Chad J. ;

Signoretti, Sabina ;

Seiler, Michael ;

Chao, Hsu ;

Dahdouli, Mike .

CANCER CELL, 2014, 26 (03) :319-330

[24] Genomic profiling in renal cell carcinoma [J].

Dizman, Nazli ;

Philip, Errol J. ;

Pal, Sumanta K. .

NATURE REVIEWS NEPHROLOGY, 2020, 16 (08) :435-451

[25] Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma [J].

Ernst, Matthew S. ;

Navani, Vishal ;

Wells, J. Connor ;

Donskov, Frede ;

Basappa, Naveen ;

Labaki, Chris ;

Pal, Sumanta K. ;

Meza, Luis ;

Wood, Lori A. ;

Ernst, D. Scott ;

Szabados, Bernadett ;

McKay, Rana R. ;

Parnis, Francis ;

Suarez, Cristina ;

Yuasa, Takeshi ;

Lalani, Aly-Khan ;

Alva, Ajjai ;

Bjarnason, Georg A. ;

Choueiri, Toni K. ;

Heng, Daniel Y. C. .

EUROPEAN UROLOGY, 2023, 84 (01) :109-116

[26] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Rioux-Leclercq, N. ;

Bex, A. ;

Khoo, V. ;

Grunwald, V. ;

Gillessen, S. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2019, 30 (05) :706-720

[27] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[28] PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients [J].

Figaroa, Orlane ;

Zondervan, Patricia ;

Kessels, Rob ;

Berkhof, Johannes ;

Aarts, Maureen ;

Hamberg, Paul ;

Los, Maartje ;

Piersma, Djura ;

Rikhof, Bart ;

Suelmann, Britt ;

Tascilar, Metin ;

van der Veldt, Astrid ;

Verhagen, Paul ;

Westgeest, Hans ;

Yildirim, Hilin ;

Bex, Axel ;

Bins, Adriaan .

EUROPEAN UROLOGY OPEN SCIENCE, 2024, 70 :28-35

[29] Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis [J].

Flanigan, RC ;

Mickisch, G ;

Sylvester, R ;

Tangen, C ;

Van Poppel, H ;

Crawford, ED .

JOURNAL OF UROLOGY, 2004, 171 (03) :1071-1076

[30] MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].

GNARRA, JR ;

TORY, K ;

WENG, Y ;

SCHMIDT, L ;

WEI, MH ;

LI, H ;

LATIF, F ;

LIU, S ;

CHEN, F ;

DUH, FM ;

LUBENSKY, I ;

DUAN, DR ;

FLORENCE, C ;

POZZATTI, R ;

WALTHER, MM ;

BANDER, NH ;

GROSSMAN, HB ;

BRAUCH, H ;

POMER, S ;

BROOKS, JD ;

ISAACS, WB ;

LERMAN, MI ;

ZBAR, B ;

LINEHAN, WM .

NATURE GENETICS, 1994, 7 (01) :85-90

← 1 2 3 4 5 6 7 8 9 10 →